Neolys Diagnostics

Executive Summary

Neolys Diagnostics is a French biotechnology company founded in 2016 and headquartered in Lyon, specializing in predictive diagnostic tests for personalized radiotherapy in oncology. The company's platform leverages analysis of the ATM protein, a key player in DNA damage repair, to assess individual patient radiosensitivity. By identifying patients who are more or less sensitive to radiation, Neolys aims to optimize radiotherapy dosing, reduce side effects, and improve treatment outcomes. The technology addresses a critical unmet need in radiation oncology, where current approaches often rely on population averages rather than individual biology. Neolys Diagnostics is positioned at the intersection of precision medicine and oncology, with potential applications across multiple cancer types. The company is privately held and appears to be in an early stage of development, given the lack of disclosed funding rounds or partnerships. Its core value proposition lies in transforming radiotherapy from a one-size-fits-all modality to a truly personalized treatment, which could significantly impact clinical practice if validated.

Upcoming Catalysts (preview)

• Q4 2026First clinical validation study results65% success
• Q2 2027CE marking for diagnostic test50% success
• Q3 2026Series A funding round60% success